Scientific Research News

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chib...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia’s litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent est...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Company (the "Options"), with effective grant dates of June 2, 2025 and June 9, 2025, depending on the appli...

FALLS CHURCH, Va.--(BUSINESS WIRE)--BAE Systems, Inc. has named Tara Olivet as its senior vice president of Finance....

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology organization developing genetic therapies for ultra-rare conditions, is proud to announce the appointment of Keith Sutton, PhD, as Chief Science Officer and the addition of Michelle Werner to its Board of Directors. These strategic additions bring deep scientific expertise and seasoned biopharmaceutical leadership to CRD as the organization continues to advance therapeutic development for rare...

AZUSA, Calif.--(BUSINESS WIRE)--History was made in Southern California when a team of surgeons achieved a medical milestone: the world’s first bladder transplant. This groundbreaking advancement gave Oscar Larrainzar, a 41-year-old man, a second chance at life—something he once thought was out of reach. While the surgeons’ achievement is historic, it is equally important to honor Amanda Cordier: a mother, wife, daughter, and organ donor. Without her—and her extraordinary gift of life—this mome...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Phare Bio, a biotech social venture using AI to combat the global antibiotic resistance crisis, has been selected to participate in the Google.org Accelerator: Generative AI – to advance its groundbreaking work in antibiotic research and development. Along with a share of $30 million in funding, Phare Bio will receive 6 months of pro bono technical expertise to support the continued buildout of Phare Bio’s AI-powered, open-access drug discovery platform – a re...

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, and Databricks, the Data and AI company, today announced a partnership to advance precision medicine for healthcare and life sciences organizations. By building on the Databricks Data Intelligence Platform and leveraging Delta Sharing, Atropos Health empowers clinicians and researchers to generate actionable, evidence-based insights to ac...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that its poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting has received the GRASP Advocate Choice Award. The poster, titled “Macroscale Genomic Alterations in Histomolecular Invasive Lobular Carcinoma Compared to Other Breast Cancer Subtypes,” was presented by Jason Mouabbi, MD, of The University of Texas MD Anderson Cancer Center, on Jun...

BOSTON--(BUSINESS WIRE)--Anodyne Nanotech, a clinical-stage biotech company, today announced new preclinical data demonstrating that administration of ANN-102 - an APJ receptor agonist via its proprietary HeroPatch™ microneedle system - significantly improved muscle strength, with efficacy equivalent to daily injections. These results lay the foundation for a novel, non-invasive, muscle-preserving therapy aimed at addressing sarcopenia, a major health challenge in aging populations. Beginning a...